Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Common Share Disclosure: Schedule of Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2015

	For the three months ended March 31,
	2015		2014
Net Loss	$	(644,606)	$	(1,344,276)
Basic and diluted:
Preferred stock cumulative dividend - Series B ⁽¹⁾		--		(22,368)
Preferred stock cumulative dividend - Series C		--		1,904
Preferred stock cumulative dividend - Series D		10,589		59,012
Income applicable to preferred stockholders		10,589		38,548
Net loss applicable to common stockholders	$	(655,195)	$	(1,382,824)